

RNS Number : 2039J
EKF Diagnostics Holdings PLC
09 June 2014

9 June 2014

**EKF Diagnostics Holdings plc
("EKF", the "Company")**

Grant of share options

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care, central laboratory and molecular diagnostics business, announces it has granted an option to acquire 1,300,000 ordinary shares of one penny each in the Company to Dr Tito Bacarese-Hamilton, the newly appointed Chief Technology Officer, at the time of his appointment. The option has been granted under the Company's Unapproved Share Option Plan.

The exercise price of the options is 35 pence per share and can be exercised at any time from 30 May 2017 onwards.

A further two tranches of 1,300,000 EKF share options will be granted to Dr Bacarese-Hamilton, one on the first anniversary of his appointment and the other on the second anniversary. These options will have an exercise price equivalent to the share price of the EKF shares on the day of grant and on the premise that certain, to be agreed, pre-conditions have been satisfied.

Dr Bacarese-Hamilton currently holds 106,429 shares in the Company.

There are now a total of 27,851,276 options over ordinary shares granted, representing approximately 6.54 per cent. of the Company's current issued share capital.

Enquiries:

EKF Diagnostics Holdings plc

David Evans, Executive Chairman
Julian Baines, CEO
Paul Foulger, CFO

Tel: 029 2071 0570

Mob: 07740 084 452
Mob: 07788 420 859
Mob: 07710 989 255

Canaccord Genuity Limited

Nominated Adviser/Corporate Broking

Lucy Tilley /Julian Feneley /Henry Fitzgerald-O'Connor /Chris Connors

Tel: 020 7523 8350

Walbrook PR Limited

Paul McManus
Paul Cornelius

Tel: 020 7933 8780 or ekf@walbrookpr.com

Mob: 07980 541 893
Mob: 07866 384 707

About EKF Diagnostics Holdings plc - www.ekfdiagnostics.com

EKF Diagnostics Holdings plc was formed in July 2010 following the acquisition of EKF-diagnostic GmbH for €14.32m and refocused its strategy to one of building a substantial point of care diagnostics business. As part of this strategy, the Group has integrated three further acquisitions, Quotient Diagnostics Limited (acquired in September 2010), Argutus Medical Limited (acquired in December 2010) and Stanbio Laboratory L.P. (acquired in June 2011). In 2013 EKF established a new subsidiary, EKF Molecular Diagnostics Ltd, to focus on molecular and companion diagnostics and acquired 360 Genomics Ltd, a business that owns diagnostics technologies for cancer gene detection.

The Company, with its head office in Cardiff and operations in London, Germany, Poland, Russia, Ireland and the US, is a leading diagnostics business, focussing on the development, production and distribution of chemical reagents and analysers for the testing of Glucose, Lactate, Haemoglobin, Haematocrit and HbA1c.

In March 2011 EKF entered into a distribution agreement with Alere Inc ("Alere"), a global diagnostics company, under which Alere was appointed the exclusive distributor of EKF's CLIA waived Hemo Control device and cuvettes in the US, Canada and United Kingdom. The device is distributed in the US under the name HemoPoint H2.

In March 2014, EKF acquired Separation Technology, Inc., a Florida based manufacturer of in vitro diagnostics devices for the haematology testing market. In April 2014, EKF completed the acquisitions of Selah Genomics Inc., a US based developer of molecular diagnostics for personalised medicine and DiaSpect Medical AB., a Swedish based manufacturer of point-of-care haemoglobin analysers.

This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSQKCDPABKDAAK admin Grant of Share Options 21767220 A Mon, 06/09/2014 - 17:59 Directors'
Dealings EKF